ClinicalTrials.gg
CompletedNCT02327169Updated Feb 25, 2020Results posted

A Study MLN2480 in Combination With MLN0128 or Alisertib, or Paclitaxel, or Cetuximab, or Irinotecan in Adult Participants With Advanced Nonhematologic Malignancies

A Phase 1 interventional study of MLN2480 and MLN0128 in Advanced Nonhematologic Malignancies, sponsored by Millennium Pharmaceuticals, Inc.. Completed at 14 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-02-25.

Sponsored by Millennium Pharmaceuticals, Inc. (part of Takeda) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
81
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

The primary purpose of this study is to determine the safety profile and the maximum tolerated doses (MTDs)/ potential recommended phase 2 doses (RP2Ds) of the combination treatments of MLN2480 + MLN0128, MLN2480 + alisertib, MLN2480 + paclitaxel, MLN2480 + cetuximab, and MLN2480 + irinotecan in participants with advanced nonhematologic malignancies.

Read the detailed description

The drug being tested in this study is called MLN2480 (TAK-580). MLN2480 was tested to evaluate side effects and determine the maximum tolerated dose (MTD) and recommended dose for future studies when administered in combination with five other medications. This study was to assess the safety of MLN2480 as well as how it is processed by the body in participants with solid nonhematologic malignancies who have failed standard therapies.

The study was to be conducted in two phases, the dose escalation phase and the dose expansion phase. A total of 71 participants were enrolled in the escalation phase. Participants in this phase were assigned to one of the five treatment groups:

  • MLN2480 + MLN0128
  • MLN2480 + Alisertib
  • MLN2480 + Paclitaxel
  • MLN2480 + Cetuximab
  • MLN2480 + Irinotecan

Once the MTD for each combination treatment arm was established in the escalation phase, one or more of the combination treatments will be selected for the expansion phase. A total of 10 participants were enrolled in the expansion phase.

This multi-centre trial was be conducted worldwide. The overall time to participate in this study is approximately 14 months. Participants made multiple visits to the clinic including an end of study visit 30 days after last dose of study drug for a follow-up assessment.

02

Conditions studied

  • Advanced Nonhematologic Malignancies

Keywords

  • Drug therapy
03

In context

Lead sponsor

Millennium Pharmaceuticals, Inc. is the lead sponsor of 178 studies on the registry; none are open to participants now.

Of its 74 completed or terminated interventional studies of FDA-regulated products, 73 (99%) have results posted.

First submitted after Millennium Pharmaceuticals, Inc. became part of Takeda.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

All Treatment Arms:

  1. Male or female participants 18 years or older.
  2. Participants who, in the opinion of the treating physician, have failed standard therapies and for whom a phase 1 trial is an appropriate option.
  3. Radiographically or clinically evaluable tumor. For expansion phase: Tumors must be measurable and of the protocol specified genetic mutational status, where applicable.
  4. Recovered (ie, less than or equal to [\<=] Grade 1 toxicity) from adverse effects (except alopecia) of prior therapy.
  5. (ECOG) performance status 0-1.
  6. Expected survival time of at least 3 months in the opinion of the investigator.
  7. Block of banked tumor tissue and/or greater than or equal to (>=) 10 unstained slides. Participants who satisfy all other eligibility criteria but do not have banked tissue/slides may be asked to consent to baseline .
  8. Suitable vein access for the study-required blood sampling.
  9. Thyroid function tests consistent with stable thyroid function. Note: Participants on a stable dose of thyroid replacement therapy for a suggested minimum of 12 weeks before Cycle 1, Day 1 are eligible.
  10. (LVEF) of 50 percent (%) or greater, as measured by echocardiogram (ECHO) or multiple-gated acquisition scan (MUGA), within 28 days before the first dose of MLN2480
  11. Female participants who are for at least 1 year, surgically sterile, or agree to practice 2 effective methods of through 120 days (4 months) after the last dose of study drug for participants in Arms 1, 2, and 5, and through 6 months for participants in Arms 3 and 4, or agree to practice true abstinence.
  12. Male participants who, even if surgically sterilized, agree to practice effective barrier contraception through 120 days (4 months) after the last dose of study drug for participants in Arms 1, 2, and 5, and through 6 months for participants in Arms 3, and 4, or agree to practice true abstinence.
  13. Additional inclusion criteria for arm 3 expansion only (MLN2480 + paclitaxel):

    a. Participants with Kirsten rat sarcoma viral oncogene homolog (KRAS) exon 2 or BRAF non-V600 mutation-positive non-small cell lung cancer (NSCLC) who have received a minimum of 1 but not more than 2 prior cytotoxic-approved regimens.

  14. Additional inclusion criteria for arms 4 and 5 expansion only (MLN2480 + cetuximab; MLN2480 + irinotecan):

    1. Participants with CRC who have received a minimum of 1 but not more than 2 prior cytotoxic-approved regimens.

Exclusion criteria

Exclusion Criteria:

All treatment arms:

  1. Female participants who are pregnant or currently breastfeeding.
  2. History of any serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with safe protocol completion.
  3. History of uncontrolled unless: previously treated with surgery, whole-brain radiation, or stereotactic radiosurgery; stable disease for >= 60 days without use (or stable steroid dose established for >= 28 days before the first dose of MLN2480).
  4. Ongoing seizure disorder or a requirement for antiepileptics.
  5. Recent prior therapies, including: chemotherapy and hormonal therapy \<= 4 weeks or 4 half lives, whichever occurs first, before administration of study drug; immunotherapy/monoclonal antibody use \<= 4 weeks before administration of MLN2480; or radiation therapy \<= 3 weeks before administration of study drug.
  6. Chronic therapeutic corticosteroid use with the exception of replacement therapy for adrenal insufficiency or corticosteroid inhalers.
  7. Known history of infection, , or ; Prior allogeneic bone marrow or organ transplantation, or active condition of chronic immune suppression is not allowed.
  8. Concomitant use, or administration \<= 14 days before first dose of study drug(s), of enzyme inducers.
  9. Treatment with gemfibrozil (strong Cytochrome P4502C8 [CYP2C8] inhibitor) within 14 days before the first dose of MLN2480.
  10. History of or current illicit drug use, drug abuse, or alcohol abuse.
  11. Major surgery within 14 days before the first dose of study drug.
  12. Inability to comply with study requirements.
  13. Other unspecified reasons that, in the opinion of the investigator or Millennium, make the participant unsuitable for enrollment.
  14. Additional exclusion criteria for arms 3, 5, and 6 expansion only (MLN2480 + paclitaxel; MLN2480 + irinotecan; MLN2480 monotherapy):

    a. Prior treatment with rapidly accelerated fibrosarcoma (RAF), extracellular signal-regulated kinases (MEK), or other inhibitors of the mitogen-activated protein kinase (MAPK) pathway.

  15. Additional exclusion criteria for arm 2 only (MLN2480 + alisertib):

    a. History of uncontrolled sleep apnea syndrome and other conditions that could result in excessive daytime sleepiness, such as severe .

  16. Additional exclusion criteria for arm 3 only (MLN2480 + paclitaxel):

    a. Known to paclitaxel, or its components or other drugs formulated in Cremophor® EL (polyoxyethylated castor oil).

  17. Additional exclusion criteria for arm 5 only (MLN2480 + irinotecan):

    1. Use of strong or moderate Cytochrome P4503A () inhibitors \<= days of the first dose of irinotecan.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
81 participants (actual)

Study arms

  • Experimental
    MLN2480 + MLN0128

    Dose Escalation Phase: MLN2480 100 mg, tablets, orally, once on protocol specified days of a 28-day cycle for up to 12 cycles, and MLN0128 2 mg, capsules, orally, once on protocol specified days of a 28-day cycle for up to 12 cycles.

    Drug: MLN2480 · Drug: MLN0128

  • Experimental
    MLN2480 + Alisertib

    Dose Escalation Phase: MLN2480 100-200 mg, tablets, orally, once on protocol specified days of a 28-day cycle for up to 12 cycles, and alisertib 30-40 mg, tablets, orally, twice daily (BID) on protocol specified days of a 28-day cycle for up to 12 cycles. The doses of MLN2480 and alisertib were modified during this phase based on tolerability during each 28-day cycle.

    Drug: MLN2480 · Drug: Alisertib

  • Experimental
    MLN2480 + Paclitaxel

    Dose Escalation Phase: MLN2480 100-200 mg, tablets, orally, once on protocol specified days of a 28-day cycle for up to 12 cycles, and paclitaxel 80 milligram per square meter (mg/m\^2), intravenous (IV) infusion, once weekly (QW) for 3 weeks in each 28-day cycle for up to 12 cycles or MLN2480 400-600 mg tablets, orally, QW on protocol specified days of a 28-day cycle for up to 12 cycles, and paclitaxel 80 mg/m\^2, IV infusion, QW for 3 weeks in each 28-day cycle for up to 12 cycles The dose of MLN2480 was modified during this phase based on tolerability during each 28-day cycle. Any changes in paclitaxel dose was based on the standard of care.

    Drug: MLN2480 · Drug: Paclitaxel

  • Experimental
    MLN2480 + Cetuximab

    Dose Escalation Phase: MLN2480 400-600 mg, tablets, orally, once on protocol specified days of a 28-day cycle for up to 12 cycles, and cetuximab administered intravenously at a loading dose of 400 mg/m\^2 (cycle 1 Day 1), then at 250 mg/m\^2 QW on Days 8, 15, and 22 of cycle 1 and Days 1, 8, 15, and 22 in each additional 28-day cycle for up to 12 cycles. The dose of MLN2480 was modified during this phase based on tolerability during each 28-day cycle. Any changes in cetuximab dose was based on the standard of care.

    Drug: MLN2480 · Drug: Cetuximab

  • Experimental
    ML2480 + Irinotecan

    Dose Escalation Phase: MLN2480 400-600 mg, tablets, orally, once on protocol specified days of a 28-day cycle for up to 12 cycles, and irinotecan 180 mg/m\^2, IV infusion over 90 minutes, every other week (Q2W) for 2 weeks in each 28-day cycle for up to 12 cycles. The dose of MLN2480 was modified during this phase based on tolerability during each 28-day cycle. Any changes in irinotecan dose was based on the standard of care.

    Drug: MLN2480 · Drug: Irinotecan

  • Experimental
    MLN2480 600 mg + Paclitaxel 80 mg (Dose Expansion Phase)

    Dose Expansion Phase: MLN2480 600 mg, tablets, orally, once per week on Days 2, 9, 16 and 23 of a 28-day cycle for up to 12 cycles, and paclitaxel 80 mg, capsules, orally, once on 1, 8, and 15 of a 28-day cycle for up to 12 cycles.

    Drug: MLN2480

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product; the untoward medical occurrence does not necessarily have a causal relationship with this treatment. An SAE means any untoward medical occurrence that at any dose results in death, is life-threatening, requires in patient hospitalization or prolongation of an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly/birth defect or is a medically important event.

    Time frame: From Day 1, Cycle 1 through 30 days after the last dose of study drug (up to 13 months)

  2. Number of Participants With Dose-Limiting Toxicities (DLTs)

    DLT was defined using National Cancer Institute Common Terminology Criteria for Adverse Events version 4.03 and included: any drug-related hematologic toxicity ≥Grade 4 with the exception of Grade 4 neutropenia \<7 days duration; Grade 3 or 4 neutropenia with fever \>38.5 degrees Celsius and/or infection or neutropenia requiring colony-stimulating factor OR non-hematologic DLTs that were any Grade 3, 4, or 5 toxicity with the following exceptions: Grade 3 nausea, vomiting, diarrhea, and dehydration occurring in a setting of inadequate treatment; inadequately treated hypersensitivity reactions; Grade 3 elevated transaminases or urine electrolyte abnormality ≤1 week in duration; Grade 3 serum electrolyte abnormality ≤72 hours in duration. DLTs also included: drug-related adverse experience that lead to a dose modification; unresolved drug-related toxicity resulted in delay in initiation of Cycle 2.

    Time frame: From Day 1, Cycle 1 through 30 days after the last dose in Cycle 1 (up to 8 weeks)

  3. Maximum Tolerated Dose (MTD) for MLN2480

    Time frame: Day 1, Cycle 1 up to 28 days

  4. Recommended Phase 2 Dose (RP2D) of MLN2480

    Time frame: Day 1, Cycle 1 up to 28 days

Secondary outcomes

  1. Cmax : Maximum Observed Plasma Concentration for MLN2480

    Time frame: Cycle 1, Day 10 pre-dose and at multiple timepoints (Up to 48 hours) post-dose

  2. Cmax: Maximum Observed Plasma Concentration for MLN0128

    Time frame: Cycle 1, Day 10 pre-dose and at multiple timepoints (Up to 48 hours) post-dose

  3. Cmax: Maximum Observed Plasma Concentration for Alisertib

    Time frame: Cycle 1, Day 10 pre-dose and at multiple timepoints (Up to 48 hours) post-dose

  4. Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for MLN2480

    Time frame: Cycle 1, Day 10 pre-dose and at multiple timepoints (Up to 48 hours) post-dose

  5. Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for MLN0128

    Time frame: Cycle 1, Day 10 pre-dose and at multiple timepoints (Up to 48 hours) post-dose

  6. Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for Alisertib

    Time frame: Cycle 1, Day 10 pre-dose and at multiple timepoints (Up to 48 hours) post-dose

  7. AUC(0-tau): Area Under the Plasma Concentration-time Curve From Time 0 to Time Tau Over the Dosing Interval for MLN2480

    Time frame: Cycle 1, Day 10 pre-dose and at multiple timepoints (Up to 48 hours) post-dose

  8. AUC(0-tau): Area Under the Plasma Concentration-time Curve From Time 0 to Time Tau Over the Dosing Interval for MLN0128

    Time frame: Cycle 1, Day 10 pre-dose and at multiple timepoints (Up to 48 hours) post-dose

  9. AUC(0-tau): Area Under the Plasma Concentration-time Curve From Time 0 to Time Tau Over the Dosing Interval for Alisertib

    Time frame: Cycle 1, Day 10 pre-dose and at multiple timepoints (Up to 48 hours) post-dose

  10. Cmax: Maximum Observed Plasma Concentration for Paclitaxel

    Time frame: Cycle 1, Day 15 pre-dose and at multiple timepoints (Up to 48 hours) post-dose

  11. AUC(0-last): Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Paclitaxel

    Time frame: Cycle 1, Day 15 pre-dose and at multiple timepoints (Up to 48 hours) post-dose

  12. AUC(0-inf): Area Under the Plasma Concentration-time Curve From Time 0 to Infinity, Calculated Using the Observed Value of the Last Quantifiable Concentration for Paclitaxel

    Time frame: Cycle 1, Day 15 pre-dose and at multiple timepoints (Up to 48 hours) post-dose

  13. Terminal Elimination Half-life (T1/2) for Paclitaxel

    Time frame: Cycle 1, Day 15 pre-dose and at multiple timepoints (Up to 48 hours) post-dose

  14. Objective Response Rate (ORR) Based on Response Evaluation Criteria in Solid Tumors (RECIST)

    ORR was defined as the percentage of participants with complete response (CR) or partial response (PR) using Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1. CR: Disappearance of all target lesions, non-target lesions, no new lesions, and normalization of tumor marker level. PR: At least a 30% decrease in the sum of diameters of target lesions, no progression in non-target lesion, and no new lesions.

    Time frame: Baseline then every 2 cycles beginning at Cycle 2, Day 27, until disease progression, death or end of study (Up to 13 months)

  15. Duration of Response

    Duration of Response (DOR) was defined as the time in months from the first documented CR or PR per RECIST v. 1.1 to disease recurrence or disease progression (PD) whichever occurs first.

    Time frame: From first documented response until disease progression (Up to 13 months)

  16. Time to Response

    Time to response was defined as the time in months from the date of first dose of study treatment to the date of the first documentation of a PR or better response.

    Time frame: From date of enrollment to the date of the first documentation of a confirmed response (Up to 13 months)

  17. Progression Free Survival (PFS)

    PFS is defined as the time in months from the date of first study drug administration to the date of first documented PD or death due to any cause. PD was based on response evaluation criteria in solid tumors (RECIST V1.1), defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.

    Time frame: Baseline then every 2 cycles beginning at Cycle 2, Day 27, until disease progression, death or end of study (Approximately up to 13 months)

07

Results

Posted Feb 25, 2020

Participant flow

Participants took part in the study at 14 investigative sites in the United States, France, Spain, and United Kingdom from 14 September 2016 to 02 July 2018.

Participant flow — Overall Study
MilestoneMLN2480 100 mg + MLN0128 2 mgMLN2480 100 mg + Alisertib 30 mgMLN2480 160 mg + Alisertib 30 mgMLN2480 200 mg + Alisertib 30 mgMLN2480 100 mg + Alisertib 40 mgMLN2480 100 mg + Paclitaxel 80 mg/m^2MLN2480 160 mg + Paclitaxel 80 mg/m^2MLN2480 200 mg + Paclitaxel 80 mg/m^2MLN2480 400 mg + Paclitaxel 80 mg/m^2MLN2480 600 mg + Paclitaxel 80 mg/m^2MLN2480 400 mg + Cetuximab 250 mg/m^2MLN2480 600 mg + Cetuximab 250 mg/m^2ML2480 300 mg + Irinotecan 180 mg/m^2ML2480 400 mg + Irinotecan 180 mg/m^2Dose Expansion: MLN2480 600 mg + Paclitaxel 80 mg/m^2
Started4373843468671710
Completed000000000000000
Not completed4373843468671710
Withdrew: Progressive disease134343334443133
Withdrew: Adverse event201010000203021
Withdrew: Symptomatic deterioration001011002100021
Withdrew: Reason not specified001000000121002
Withdrew: Withdrawal by subject100010010000003
Withdrew: Lost to follow-up000010000000000

Outcome measures

PrimaryNumber of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product; the untoward medical occurrence does not necessarily have a causal relationship with this treatment. An SAE means any untoward medical occurrence that at any dose results in death, is life-threatening, requires in patient hospitalization or prolongation of an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly/birth defect or is a medically important event.

Time frame:
From Day 1, Cycle 1 through 30 days after the last dose of study drug (up to 13 months)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
ParticipantsMLN2480 100 mg + MLN0128 2 mgMLN2480 100 mg + Alisertib 30 mgMLN2480 160 mg + Alisertib 30 mgMLN2480 200 mg + Alisertib 30 mgMLN2480 100 mg + Alisertib 40 mgMLN2480 100 mg + Paclitaxel 80 mg/m^2MLN2480 160 mg + Paclitaxel 80 mg/m^2MLN2480 200 mg + Paclitaxel 80 mg/m^2MLN2480 400 mg + Paclitaxel 80 mg/m^2MLN2480 600 mg + Paclitaxel 80 mg/m^2MLN2480 400 mg + Cetuximab 250 mg/m^2MLN2480 600 mg + Cetuximab 250 mg/m^2ML2480 300 mg + Irinotecan 180 mg/m^2ML2480 400 mg + Irinotecan 180 mg/m^2Dose Expansion: MLN2480 600 mg + Paclitaxel 80 mg/m^2
AEs4373843468671710
SAEs215131123423047
PrimaryNumber of Participants With Dose-Limiting Toxicities (DLTs)

DLT was defined using National Cancer Institute Common Terminology Criteria for Adverse Events version 4.03 and included: any drug-related hematologic toxicity ≥Grade 4 with the exception of Grade 4 neutropenia \<7 days duration; Grade 3 or 4 neutropenia with fever \>38.5 degrees Celsius and/or infection or neutropenia requiring colony-stimulating factor OR non-hematologic DLTs that were any Grade 3, 4, or 5 toxicity with the following exceptions: Grade 3 nausea, vomiting, diarrhea, and dehydration occurring in a setting of inadequate treatment; inadequately treated hypersensitivity reactions; Grade 3 elevated transaminases or urine electrolyte abnormality ≤1 week in duration; Grade 3 serum electrolyte abnormality ≤72 hours in duration. DLTs also included: drug-related adverse experience that lead to a dose modification; unresolved drug-related toxicity resulted in delay in initiation of Cycle 2.

Time frame:
From Day 1, Cycle 1 through 30 days after the last dose in Cycle 1 (up to 8 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Dose-Limiting Toxicities (DLTs)
ParticipantsMLN2480 100 mg + MLN0128 2 mgMLN2480 100 mg + Alisertib 30 mgMLN2480 160 mg + Alisertib 30 mgMLN2480 200 mg + Alisertib 30 mgMLN2480 100 mg + Alisertib 40 mgMLN2480 100 mg + Paclitaxel 80 mg/m^2MLN2480 160 mg + Paclitaxel 80 mg/m^2MLN2480 200 mg + Paclitaxel 80 mg/m^2MLN2480 400 mg + Paclitaxel 80 mg/m^2MLN2480 600 mg + Paclitaxel 80 mg/m^2MLN2480 400 mg + Cetuximab 250 mg/m^2MLN2480 600 mg + Cetuximab 250 mg/m^2ML2480 300 mg + Irinotecan 180 mg/m^2ML2480 400 mg + Irinotecan 180 mg/m^2Dose Expansion: MLN2480 600 mg + Paclitaxel 80 mg/m^2
Number of Participants With Dose-Limiting Toxicities (DLTs)100010001101011
PrimaryMaximum Tolerated Dose (MTD) for MLN2480
Time frame:
Day 1, Cycle 1 up to 28 days
Reported as:
Number · mg
Maximum Tolerated Dose (MTD) for MLN2480
mgMLN2480 100 mg + MLN0128 2 mgMLN2480 100 mg + Alisertib 30 mgMLN2480 160 mg + Alisertib 30 mgMLN2480 200 mg + Alisertib 30 mgMLN2480 100 mg + Alisertib 40 mgMLN2480 100 mg + Paclitaxel 80 mg/m^2MLN2480 160 mg + Paclitaxel 80 mg/m^2MLN2480 200 mg + Paclitaxel 80 mg/m^2MLN2480 400 mg + Paclitaxel 80 mg/m^2MLN2480 600 mg + Paclitaxel 80 mg/m^2MLN2480 400 mg + Cetuximab 250 mg/m^2MLN2480 600 mg + Cetuximab 250 mg/m^2ML2480 300 mg + Irinotecan 180 mg/m^2ML2480 400 mg + Irinotecan 180 mg/m^2Dose Expansion: MLN2480 600 mg + Paclitaxel 80 mg/m^2
Maximum Tolerated Dose (MTD) for MLN2480NANANANANANANANANA600NANANANANA
PrimaryRecommended Phase 2 Dose (RP2D) of MLN2480
Time frame:
Day 1, Cycle 1 up to 28 days
Reported as:
Number · mg
Recommended Phase 2 Dose (RP2D) of MLN2480
mgMLN2480 100 mg + MLN0128 2 mgMLN2480 100 mg + Alisertib 30 mgMLN2480 160 mg + Alisertib 30 mgMLN2480 200 mg + Alisertib 30 mgMLN2480 100 mg + Alisertib 40 mgMLN2480 100 mg + Paclitaxel 80 mg/m^2MLN2480 160 mg + Paclitaxel 80 mg/m^2MLN2480 200 mg + Paclitaxel 80 mg/m^2MLN2480 400 mg + Paclitaxel 80 mg/m^2MLN2480 600 mg + Paclitaxel 80 mg/m^2MLN2480 400 mg + Cetuximab 250 mg/m^2MLN2480 600 mg + Cetuximab 250 mg/m^2ML2480 300 mg + Irinotecan 180 mg/m^2ML2480 400 mg + Irinotecan 180 mg/m^2Dose Expansion: MLN2480 600 mg + Paclitaxel 80 mg/m^2
Recommended Phase 2 Dose (RP2D) of MLN2480NANANANANANANANANA600NANANANANA
SecondaryCmax : Maximum Observed Plasma Concentration for MLN2480
Time frame:
Cycle 1, Day 10 pre-dose and at multiple timepoints (Up to 48 hours) post-dose

No measurements were reported for this outcome.

SecondaryCmax: Maximum Observed Plasma Concentration for MLN0128
Time frame:
Cycle 1, Day 10 pre-dose and at multiple timepoints (Up to 48 hours) post-dose

No measurements were reported for this outcome.

SecondaryCmax: Maximum Observed Plasma Concentration for Alisertib
Time frame:
Cycle 1, Day 10 pre-dose and at multiple timepoints (Up to 48 hours) post-dose

No measurements were reported for this outcome.

SecondaryTmax: Time to Reach the Maximum Plasma Concentration (Cmax) for MLN2480
Time frame:
Cycle 1, Day 10 pre-dose and at multiple timepoints (Up to 48 hours) post-dose

No measurements were reported for this outcome.

SecondaryTmax: Time to Reach the Maximum Plasma Concentration (Cmax) for MLN0128
Time frame:
Cycle 1, Day 10 pre-dose and at multiple timepoints (Up to 48 hours) post-dose

No measurements were reported for this outcome.

SecondaryTmax: Time to Reach the Maximum Plasma Concentration (Cmax) for Alisertib
Time frame:
Cycle 1, Day 10 pre-dose and at multiple timepoints (Up to 48 hours) post-dose

No measurements were reported for this outcome.

SecondaryAUC(0-tau): Area Under the Plasma Concentration-time Curve From Time 0 to Time Tau Over the Dosing Interval for MLN2480
Time frame:
Cycle 1, Day 10 pre-dose and at multiple timepoints (Up to 48 hours) post-dose

No measurements were reported for this outcome.

SecondaryAUC(0-tau): Area Under the Plasma Concentration-time Curve From Time 0 to Time Tau Over the Dosing Interval for MLN0128
Time frame:
Cycle 1, Day 10 pre-dose and at multiple timepoints (Up to 48 hours) post-dose

No measurements were reported for this outcome.

SecondaryAUC(0-tau): Area Under the Plasma Concentration-time Curve From Time 0 to Time Tau Over the Dosing Interval for Alisertib
Time frame:
Cycle 1, Day 10 pre-dose and at multiple timepoints (Up to 48 hours) post-dose

No measurements were reported for this outcome.

SecondaryCmax: Maximum Observed Plasma Concentration for Paclitaxel
Time frame:
Cycle 1, Day 15 pre-dose and at multiple timepoints (Up to 48 hours) post-dose

No measurements were reported for this outcome.

SecondaryAUC(0-last): Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Paclitaxel
Time frame:
Cycle 1, Day 15 pre-dose and at multiple timepoints (Up to 48 hours) post-dose

No measurements were reported for this outcome.

SecondaryAUC(0-inf): Area Under the Plasma Concentration-time Curve From Time 0 to Infinity, Calculated Using the Observed Value of the Last Quantifiable Concentration for Paclitaxel
Time frame:
Cycle 1, Day 15 pre-dose and at multiple timepoints (Up to 48 hours) post-dose

No measurements were reported for this outcome.

SecondaryTerminal Elimination Half-life (T1/2) for Paclitaxel
Time frame:
Cycle 1, Day 15 pre-dose and at multiple timepoints (Up to 48 hours) post-dose

No measurements were reported for this outcome.

SecondaryObjective Response Rate (ORR) Based on Response Evaluation Criteria in Solid Tumors (RECIST)

ORR was defined as the percentage of participants with complete response (CR) or partial response (PR) using Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1. CR: Disappearance of all target lesions, non-target lesions, no new lesions, and normalization of tumor marker level. PR: At least a 30% decrease in the sum of diameters of target lesions, no progression in non-target lesion, and no new lesions.

Time frame:
Baseline then every 2 cycles beginning at Cycle 2, Day 27, until disease progression, death or end of study (Up to 13 months)
Reported as:
Number · percentage of participants
Objective Response Rate (ORR) Based on Response Evaluation Criteria in Solid Tumors (RECIST)
percentage of participantsMLN2480 100 mg + MLN0128 2 mgMLN2480 100 mg + Alisertib 30 mgMLN2480 160 mg + Alisertib 30 mgMLN2480 200 mg + Alisertib 30 mgMLN2480 100 mg + Alisertib 40 mgMLN2480 100 mg + Paclitaxel 80 mg/m^2MLN2480 160 mg + Paclitaxel 80 mg/m^2MLN2480 200 mg + Paclitaxel 80 mg/m^2MLN2480 400 mg + Paclitaxel 80 mg/m^2MLN2480 600 mg + Paclitaxel 80 mg/m^2MLN2480 400 mg + Cetuximab 250 mg/m^2MLN2480 600 mg + Cetuximab 250 mg/m^2ML2480 300 mg + Irinotecan 180 mg/m^2ML2480 400 mg + Irinotecan 180 mg/m^2Dose Expansion: MLN2480 600 mg + Paclitaxel 80 mg/m^2
Objective Response Rate (ORR) Based on Response Evaluation Criteria in Solid Tumors (RECIST)0 (0 to 0)0 (0 to 0)0 (0 to 0)0 (0 to 0)17 (1 to 64)75 (19 to 99)0 (0 to 0)0 (0 to 0)40 (5 to 85)17 (1 to 64)0 (0 to 0)0 (0 to 0)0 (0 to 0)0 (0 to 0)38 (9 to 76)
SecondaryDuration of Response

Duration of Response (DOR) was defined as the time in months from the first documented CR or PR per RECIST v. 1.1 to disease recurrence or disease progression (PD) whichever occurs first.

Time frame:
From first documented response until disease progression (Up to 13 months)
Reported as:
Median · months
Duration of Response
monthsMLN2480 100 mg + MLN0128 2 mgMLN2480 100 mg + Alisertib 30 mgMLN2480 160 mg + Alisertib 30 mgMLN2480 200 mg + Alisertib 30 mgMLN2480 100 mg + Alisertib 40 mgMLN2480 100 mg + Paclitaxel 80 mg/m^2MLN2480 160 mg + Paclitaxel 80 mg/m^2MLN2480 200 mg + Paclitaxel 80 mg/m^2MLN2480 400 mg + Paclitaxel 80 mg/m^2MLN2480 600 mg + Paclitaxel 80 mg/m^2MLN2480 400 mg + Cetuximab 250 mg/m^2MLN2480 600 mg + Cetuximab 250 mg/m^2ML2480 300 mg + Irinotecan 180 mg/m^2ML2480 400 mg + Irinotecan 180 mg/m^2Dose Expansion: MLN2480 600 mg + Paclitaxel 80 mg/m^2
Duration of Response————NA (NA to NA)3.7 (1.0 to 5.8)——6.5 (1.7 to 11.2)3.5 (NA to NA)————11.5 (NA to NA)
SecondaryTime to Response

Time to response was defined as the time in months from the date of first dose of study treatment to the date of the first documentation of a PR or better response.

Time frame:
From date of enrollment to the date of the first documentation of a confirmed response (Up to 13 months)
Reported as:
Median · months
Time to Response
monthsMLN2480 100 mg + MLN0128 2 mgMLN2480 100 mg + Alisertib 30 mgMLN2480 160 mg + Alisertib 30 mgMLN2480 200 mg + Alisertib 30 mgMLN2480 100 mg + Alisertib 40 mgMLN2480 100 mg + Paclitaxel 80 mg/m^2MLN2480 160 mg + Paclitaxel 80 mg/m^2MLN2480 200 mg + Paclitaxel 80 mg/m^2MLN2480 400 mg + Paclitaxel 80 mg/m^2MLN2480 600 mg + Paclitaxel 80 mg/m^2MLN2480 400 mg + Cetuximab 250 mg/m^2MLN2480 600 mg + Cetuximab 250 mg/m^2ML2480 300 mg + Irinotecan 180 mg/m^2ML2480 400 mg + Irinotecan 180 mg/m^2Dose Expansion: MLN2480 600 mg + Paclitaxel 80 mg/m^2
Time to Response————4.2 (NA to NA)3.7 (2.3 to 3.7)——2.7 (1.9 to 3.6)1.8 (NA to NA)————1.9 (1.9 to 2.0)
SecondaryProgression Free Survival (PFS)

PFS is defined as the time in months from the date of first study drug administration to the date of first documented PD or death due to any cause. PD was based on response evaluation criteria in solid tumors (RECIST V1.1), defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.

Time frame:
Baseline then every 2 cycles beginning at Cycle 2, Day 27, until disease progression, death or end of study (Approximately up to 13 months)
Reported as:
Median · months
Progression Free Survival (PFS)
monthsMLN2480 100 mg + MLN0128 2 mgMLN2480 100 mg + Alisertib 30 mgMLN2480 160 mg + Alisertib 30 mgMLN2480 200 mg + Alisertib 30 mgMLN2480 100 mg + Alisertib 40 mgMLN2480 100 mg + Paclitaxel 80 mg/m^2MLN2480 160 mg + Paclitaxel 80 mg/m^2MLN2480 200 mg + Paclitaxel 80 mg/m^2MLN2480 400 mg + Paclitaxel 80 mg/m^2MLN2480 600 mg + Paclitaxel 80 mg/m^2MLN2480 400 mg + Cetuximab 250 mg/m^2MLN2480 600 mg + Cetuximab 250 mg/m^2ML2480 300 mg + Irinotecan 180 mg/m^2ML2480 400 mg + Irinotecan 180 mg/m^2Dose Expansion: MLN2480 600 mg + Paclitaxel 80 mg/m^2
Progression Free Survival (PFS)0.5 (NA to NA)1.9 (1.1 to 16.6)3.7 (0.4 to 4.6)1.9 (1.7 to 4.6)9.5 (0.6 to 9.7)5.3 (1.3 to 9.5)5.5 (1.5 to 7.4)2.9 (1.9 to 3.7)7.6 (3.6 to 14.7)3.3 (1.8 to NA)2.2 (1.3 to NA)1.7 (1.0 to 5.4)3.6 (NA to NA)4.7 (1.8 to NA)5.7 (2.2 to 13.3)

Adverse events

Collected over AEs were recorded from the first dose of study drug through 30 days after the last dose of study drug or the start of subsequent antineoplastic therapy, whichever occurred first. SAEs were collected from the signing of Informed Consent through 30 days after the last dose of study drug (Up to 13 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
MLN2480 100 mg + MLN0128 2 mg0/4 (0%)2/4 (50%)4/4 (100%)
MLN2480 100 mg + Alisertib 30 mg0/3 (0%)1/3 (33.3%)3/3 (100%)
MLN2480 160 mg + Alisertib 30 mg2/7 (28.6%)5/7 (71.4%)7/7 (100%)
MLN2480 200 mg + Alisertib 30 mg0/3 (0%)1/3 (33.3%)3/3 (100%)
MLN2480 100 mg + Alisertib 40 mg1/8 (12.5%)3/8 (37.5%)8/8 (100%)
MLN2480 100 mg + Paclitaxel 80 mg/m^20/4 (0%)1/4 (25%)4/4 (100%)
MLN2480 160 mg + Paclitaxel 80 mg/m^20/3 (0%)1/3 (33.3%)3/3 (100%)
MLN2480 200 mg + Paclitaxel 80 mg/m^20/4 (0%)2/4 (50%)4/4 (100%)
MLN2480 400 mg + Paclitaxel 80 mg/m^20/6 (0%)3/6 (50%)6/6 (100%)
MLN2480 600 mg + Paclitaxel 80 mg/m^20/8 (0%)4/8 (50%)8/8 (100%)
MLN2480 400 mg + Cetuximab 250 mg/m^22/6 (33.3%)2/6 (33.3%)6/6 (100%)
MLN2480 600 mg + Cetuximab 250 mg/m^22/7 (28.6%)3/7 (42.9%)7/7 (100%)
ML2480 300 mg + Irinotecan 180 mg/m^20/1 (0%)0/1 (0%)1/1 (100%)
ML2480 400 mg + Irinotecan 180 mg/m^20/7 (0%)4/7 (57.1%)7/7 (100%)
Dose Expansion: MLN2480 600 mg + Paclitaxel 80 mg/m^22/10 (20%)7/10 (70%)10/10 (100%)
Most frequent serious events
Showing 10 of 52
Most frequent serious events
EventMLN2480 100 mg + MLN0128 2 mgMLN2480 100 mg + Alisertib 30 mgMLN2480 160 mg + Alisertib 30 mgMLN2480 200 mg + Alisertib 30 mgMLN2480 100 mg + Alisertib 40 mgMLN2480 100 mg + Paclitaxel 80 mg/m^2MLN2480 160 mg + Paclitaxel 80 mg/m^2MLN2480 200 mg + Paclitaxel 80 mg/m^2MLN2480 400 mg + Paclitaxel 80 mg/m^2MLN2480 600 mg + Paclitaxel 80 mg/m^2MLN2480 400 mg + Cetuximab 250 mg/m^2MLN2480 600 mg + Cetuximab 250 mg/m^2ML2480 300 mg + Irinotecan 180 mg/m^2ML2480 400 mg + Irinotecan 180 mg/m^2Dose Expansion: MLN2480 600 mg + Paclitaxel 80 mg/m^2
Abdominal painGastrointestinal disorders0/40/30/71/30/81/40/31/40/60/80/60/70/11/70/10
NauseaGastrointestinal disorders0/40/30/71/30/80/40/30/40/60/81/60/70/12/70/10
VomitingGastrointestinal disorders0/40/30/71/30/80/40/30/40/60/81/60/70/10/70/10
Post-tussive vomitingGastrointestinal disorders0/40/30/71/30/80/40/30/40/60/80/60/70/10/70/10
Small intestinal obstructionGastrointestinal disorders0/41/30/70/30/80/40/30/41/60/80/60/70/10/70/10
PneumoniaInfections and infestations0/40/31/71/30/80/40/30/40/60/80/60/70/10/71/10
Splenic haemorrhageBlood and lymphatic system disorders0/40/30/70/30/80/41/30/40/60/80/60/70/10/70/10
Febrile neutropeniaBlood and lymphatic system disorders0/40/30/70/31/80/40/30/40/60/80/60/70/12/70/10
Urinary tract infectionInfections and infestations1/40/30/70/30/80/40/30/40/60/80/60/70/10/70/10
Pulmonary oedemaRespiratory, thoracic and mediastinal disorders0/40/30/70/30/80/40/31/40/60/80/60/70/10/70/10
Most frequent other events
Showing 10 of 283
Most frequent other events
EventMLN2480 100 mg + MLN0128 2 mgMLN2480 100 mg + Alisertib 30 mgMLN2480 160 mg + Alisertib 30 mgMLN2480 200 mg + Alisertib 30 mgMLN2480 100 mg + Alisertib 40 mgMLN2480 100 mg + Paclitaxel 80 mg/m^2MLN2480 160 mg + Paclitaxel 80 mg/m^2MLN2480 200 mg + Paclitaxel 80 mg/m^2MLN2480 400 mg + Paclitaxel 80 mg/m^2MLN2480 600 mg + Paclitaxel 80 mg/m^2MLN2480 400 mg + Cetuximab 250 mg/m^2MLN2480 600 mg + Cetuximab 250 mg/m^2ML2480 300 mg + Irinotecan 180 mg/m^2ML2480 400 mg + Irinotecan 180 mg/m^2Dose Expansion: MLN2480 600 mg + Paclitaxel 80 mg/m^2
HypophosphataemiaMetabolism and nutrition disorders1/40/36/72/31/80/43/32/44/67/86/64/70/15/76/10
Decreased appetiteMetabolism and nutrition disorders2/41/35/71/35/82/42/31/42/61/80/61/71/12/75/10
NauseaGastrointestinal disorders2/41/33/71/33/83/41/33/43/61/80/62/71/14/76/10
Abdominal painGastrointestinal disorders0/41/30/70/31/81/40/31/43/61/81/62/71/12/72/10
FatigueGeneral disorders3/43/35/71/35/82/42/31/43/63/80/62/71/13/72/10
ChillsGeneral disorders1/40/31/70/31/80/40/30/42/60/80/60/71/11/70/10
AlopeciaSkin and subcutaneous tissue disorders0/42/31/71/33/83/41/32/43/61/80/60/71/11/73/10
RhinorrhoeaRespiratory, thoracic and mediastinal disorders0/40/30/70/30/80/40/30/40/60/80/60/71/10/70/10
AnaemiaBlood and lymphatic system disorders1/40/35/70/35/80/43/33/44/64/80/63/71/15/75/10
Eye painEye disorders0/40/30/70/30/81/40/30/40/60/80/60/71/10/70/10

Baseline characteristics

Safety population, all participants who received any amount of MLN2480.

Age, Continuous
Age, Continuous(years)MLN2480 100 mg + MLN0128 2 mgMLN2480 100 mg + Alisertib 30 mgMLN2480 160 mg + Alisertib 30 mgMLN2480 200 mg + Alisertib 30 mgMLN2480 100 mg + Alisertib 40 mgMLN2480 100 mg + Paclitaxel 80 mg/m^2MLN2480 160 mg + Paclitaxel 80 mg/m^2MLN2480 200 mg + Paclitaxel 80 mg/m^2MLN2480 400 mg + Paclitaxel 80 mg/m^2MLN2480 600 mg + Paclitaxel 80 mg/m^2MLN2480 400 mg + Cetuximab 250 mg/m^2MLN2480 600 mg + Cetuximab 250 mg/m^2ML2480 300 mg + Irinotecan 180 mg/m^2ML2480 400 mg + Irinotecan 180 mg/m^2Dose Expansion: MLN2480 600 mg + Paclitaxel 80 mg/m^2Total
Mean57.5 (48 to 61)48.0 (37 to 63)60.9 (24 to 77)51.0 (30 to 64)68.0 (59 to 77)66.0 (54 to 74)60.3 (57 to 65)70.0 (62 to 78)54.2 (41 to 67)65.9 (46 to 77)52.8 (37 to 66)60.1 (48 to 70)62.0 (62 to 62)62.3 (46 to 75)63.9 (57 to 75)62.3 (24 to 78)
Sex: Female, Male
Sex: Female, Male(Participants)MLN2480 100 mg + MLN0128 2 mgMLN2480 100 mg + Alisertib 30 mgMLN2480 160 mg + Alisertib 30 mgMLN2480 200 mg + Alisertib 30 mgMLN2480 100 mg + Alisertib 40 mgMLN2480 100 mg + Paclitaxel 80 mg/m^2MLN2480 160 mg + Paclitaxel 80 mg/m^2MLN2480 200 mg + Paclitaxel 80 mg/m^2MLN2480 400 mg + Paclitaxel 80 mg/m^2MLN2480 600 mg + Paclitaxel 80 mg/m^2MLN2480 400 mg + Cetuximab 250 mg/m^2MLN2480 600 mg + Cetuximab 250 mg/m^2ML2480 300 mg + Irinotecan 180 mg/m^2ML2480 400 mg + Irinotecan 180 mg/m^2Dose Expansion: MLN2480 600 mg + Paclitaxel 80 mg/m^2Total
Female33416223542403547
Male10322211144314534
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)MLN2480 100 mg + MLN0128 2 mgMLN2480 100 mg + Alisertib 30 mgMLN2480 160 mg + Alisertib 30 mgMLN2480 200 mg + Alisertib 30 mgMLN2480 100 mg + Alisertib 40 mgMLN2480 100 mg + Paclitaxel 80 mg/m^2MLN2480 160 mg + Paclitaxel 80 mg/m^2MLN2480 200 mg + Paclitaxel 80 mg/m^2MLN2480 400 mg + Paclitaxel 80 mg/m^2MLN2480 600 mg + Paclitaxel 80 mg/m^2MLN2480 400 mg + Cetuximab 250 mg/m^2MLN2480 600 mg + Cetuximab 250 mg/m^2ML2480 300 mg + Irinotecan 180 mg/m^2ML2480 400 mg + Irinotecan 180 mg/m^2Dose Expansion: MLN2480 600 mg + Paclitaxel 80 mg/m^2Total
Hispanic or Latino0001001000000002
Not Hispanic or Latino43708314575417665
Unknown or Not Reported00020110111300414
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)MLN2480 100 mg + MLN0128 2 mgMLN2480 100 mg + Alisertib 30 mgMLN2480 160 mg + Alisertib 30 mgMLN2480 200 mg + Alisertib 30 mgMLN2480 100 mg + Alisertib 40 mgMLN2480 100 mg + Paclitaxel 80 mg/m^2MLN2480 160 mg + Paclitaxel 80 mg/m^2MLN2480 200 mg + Paclitaxel 80 mg/m^2MLN2480 400 mg + Paclitaxel 80 mg/m^2MLN2480 600 mg + Paclitaxel 80 mg/m^2MLN2480 400 mg + Cetuximab 250 mg/m^2MLN2480 600 mg + Cetuximab 250 mg/m^2ML2480 300 mg + Irinotecan 180 mg/m^2ML2480 400 mg + Irinotecan 180 mg/m^2Dose Expansion: MLN2480 600 mg + Paclitaxel 80 mg/m^2Total
White43618424366417564
Black or African American0000001010000002
Other0010000010000013
Not Reported00020000120300412
Height
Height(centimetres (cm))MLN2480 100 mg + MLN0128 2 mgMLN2480 100 mg + Alisertib 30 mgMLN2480 160 mg + Alisertib 30 mgMLN2480 200 mg + Alisertib 30 mgMLN2480 100 mg + Alisertib 40 mgMLN2480 100 mg + Paclitaxel 80 mg/m^2MLN2480 160 mg + Paclitaxel 80 mg/m^2MLN2480 200 mg + Paclitaxel 80 mg/m^2MLN2480 400 mg + Paclitaxel 80 mg/m^2MLN2480 600 mg + Paclitaxel 80 mg/m^2MLN2480 400 mg + Cetuximab 250 mg/m^2MLN2480 600 mg + Cetuximab 250 mg/m^2ML2480 300 mg + Irinotecan 180 mg/m^2ML2480 400 mg + Irinotecan 180 mg/m^2Dose Expansion: MLN2480 600 mg + Paclitaxel 80 mg/m^2Total
Mean168.9 (158 to 191)163.4 (158 to 173)166.7 (156 to 175)160.3 (158 to 163)164.5 (158 to 171)167.0 (155 to 178)167.7 (161 to 175)166.3 (161 to 176)159.7 (152 to 168)167.3 (147 to 183)169.8 (159 to 180)167.4 (147 to 180)182.5 (182.5 to 182.5)172.3 (161 to 182)162.7 (154 to 173)164.7 (147 to 191)
Weight
Weight(kilograms (kg))MLN2480 100 mg + MLN0128 2 mgMLN2480 100 mg + Alisertib 30 mgMLN2480 160 mg + Alisertib 30 mgMLN2480 200 mg + Alisertib 30 mgMLN2480 100 mg + Alisertib 40 mgMLN2480 100 mg + Paclitaxel 80 mg/m^2MLN2480 160 mg + Paclitaxel 80 mg/m^2MLN2480 200 mg + Paclitaxel 80 mg/m^2MLN2480 400 mg + Paclitaxel 80 mg/m^2MLN2480 600 mg + Paclitaxel 80 mg/m^2MLN2480 400 mg + Cetuximab 250 mg/m^2MLN2480 600 mg + Cetuximab 250 mg/m^2ML2480 300 mg + Irinotecan 180 mg/m^2ML2480 400 mg + Irinotecan 180 mg/m^2Dose Expansion: MLN2480 600 mg + Paclitaxel 80 mg/m^2Total
Mean71.55 (49.5 to 111.8)80.53 (68.1 to 96.1)84.62 (56.5 to 137.6)74.15 (71.0 to 77.3)63.59 (44.0 to 79.5)86.63 (82.9 to 95.5)77.40 (60.1 to 109.1)65.45 (48.0 to 81.8)67.92 (53.2 to 92.0)65.79 (44.7 to 99.0)76.22 (55.9 to 90.0)71.39 (50.0 to 99.0)86.50 (86.5 to 86.5)74.97 (60.4 to 95.0)67.65 (40.0 to 91.9)70.31 (40.0 to 137.6)
Body Surface Area (BSA)
Body Surface Area (BSA)(square meters (m^2))MLN2480 100 mg + MLN0128 2 mgMLN2480 100 mg + Alisertib 30 mgMLN2480 160 mg + Alisertib 30 mgMLN2480 200 mg + Alisertib 30 mgMLN2480 100 mg + Alisertib 40 mgMLN2480 100 mg + Paclitaxel 80 mg/m^2MLN2480 160 mg + Paclitaxel 80 mg/m^2MLN2480 200 mg + Paclitaxel 80 mg/m^2MLN2480 400 mg + Paclitaxel 80 mg/m^2MLN2480 600 mg + Paclitaxel 80 mg/m^2MLN2480 400 mg + Cetuximab 250 mg/m^2MLN2480 600 mg + Cetuximab 250 mg/m^2ML2480 300 mg + Irinotecan 180 mg/m^2ML2480 400 mg + Irinotecan 180 mg/m^2Dose Expansion: MLN2480 600 mg + Paclitaxel 80 mg/m^2Total
Mean1.818 (1.50 to 2.43)1.906 (1.74 to 2.05)1.961 (1.59 to 2.57)1.817 (1.77 to 1.87)1.698 (1.41 to 1.91)2.003 (1.89 to 2.12)1.884 (1.67 to 2.30)1.732 (1.47 to 2.00)1.726 (1.51 to 2.01)1.738 (1.37 to 2.22)1.893 (1.61 to 2.12)1.814 (1.43 to 2.22)2.094 (2.094 to 2.094)1.925 (1.69 to 2.19)1.740 (1.31 to 2.06)1.846 (1.31 to 2.57)
08

Study locations

14 sites
  • Massachusetts General Hospital Cancer Center
    Boston, Massachusetts 2114, United States
  • Beth Israel Deaconess Medical Center
    Boston, Massachusetts 2115, United States
  • Dana Farber Cancer Institute
    Boston, Massachusetts 2115, United States
  • Fox Chase Cancer Center
    Philadelphia, Pennsylvania 19111, United States
  • The University of Texas MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Institut Bergonie
    Bordeaux cedex, Gironde 33076, France
  • Institut Claudius Regaud-Oncopole
    Toulouse cedex 09, Haute Garonne 31059, France
  • Institut Gustave Roussy
    Villejuif cedex, Val De Marne 94805, France
  • Hospital Universitari Vall d'Hebron
    Barcelona, 8035, Spain
  • START Madrid. Fundacion Jimenez Diaz
    Madrid, 28040, Spain
  • Hospital Clinico Universitario Virgen de la Victoria
    Malaga, 29010, Spain
  • Sarah Cannon Research Institure UK
    London, Greater London W1G 6AD, United Kingdom
  • The Chrisie
    Manchester, Greater Manchester M20 4BX, United Kingdom
  • Churchill Hospital
    Oxford, Oxfordshire OX3 7LJ, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Takeda makes patient-level, de-identified data sets and associated documents available for all interventional studies after applicable marketing approvals and commercial availability have been received (or program is completely terminated), an opportunity for the primary publication of the research and final report development has been allowed, and other criteria have been met as set forth in Takeda's Data Sharing Policy (see www.TakedaClinicalTrials.com for details). To obtain access, researchers must submit a legitimate academic research proposal for adjudication by an independent review panel, who will review the scientific merit of the research and the requestor's qualifications and conflict of interest that can result in potential bias. Once approved, qualified researchers who sign a data sharing agreement are provided access to these data in a secure research environment.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2015 to primary completion in Jul 2018, 41 months.

Results were first posted in Feb 2020, 1 year 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 23, 2014
First posted
Dec 30, 2014
StartActual
Jan 14, 2015
Primary completionActual
Jul 2, 2018
CompletionActual
Jul 2, 2018
Results first posted
Feb 25, 2020
Last update
Feb 25, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 25, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02327169
Responsible party
Sponsor
First posted
Dec 30, 2014
Start date
Jan 14, 2015
Primary completion
Jul 2, 2018
Completion
Jul 2, 2018
Results posted
Feb 25, 2020
Last update
Feb 25, 2020

Study contacts

Medical Director Clinical Science
study director · Takeda

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tovorafenib

Start the discussion